Effective management of venous thromboembolism in the community: non-vitamin K antagonist oral anticoagulants

References

• CohenATAgnelliGAndersonFAVTE Impact Assessment Group in Europe (VITAE)Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortalityThromb Haemost200798475676417938798
   PubMed Web of Science ®Google Scholar
• AgenoWGallusASWittkowskyAAmerican College of Chest PhysiciansOral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelinesChest20121412 supple44Se88S22315269
   PubMed Web of Science ®Google Scholar
• HuttenBAPrinsMHDuration of treatment with vitamin K antagonists in symptomatic venous thromboembolismCochrane Database Syst Rev20003CD00136710908494
   PubMedGoogle Scholar
• CapriniJAHyersTMCompliance with antithrombotic guidelines: current practice, barriers, and strategies for improvementManag Care2006159496617036939
   PubMedGoogle Scholar
• MerliGImproving venous thromboembolism performance: a comprehensive guide for physicians and hospitalistsHosp Pract (1995)201038371620499768
   PubMedGoogle Scholar
• VatsVNutescuEATheobaldJCWojtynekJESchumockGTSurvey of hospitals for guidelines, policies, and protocols for anticoagulantsAm J Health Syst Pharm200764111203120817519463
   PubMed Web of Science ®Google Scholar
• PrandoniPVillaltaSBagatellaPThe clinical course of deep-vein thrombosis. Prospective long-term follow-up of 528 symptomatic patientsHaematologica19978244234289299855
   PubMed Web of Science ®Google Scholar
• Pradaxa^® (dabigatran etexilate) summary of product characteristicsIngelheim am RheinBoehringer Ingelheim International GmbH2015
   Google Scholar
• Lixiana^® (edoxaban) summary of product characteristicsMunichDaiichi Sankyo Europe GmbH2015
   Google Scholar
• Xarelto^® (rivaroxaban) summary of product characteristicsBerlinBayer Pharma AG2015
   Google Scholar
• Eliquis^® (apixaban) summary of product characteristicsUxbridgeBristol-Myers Squibb, Pfizer2015
   Google Scholar
• National Institute for Health and Care Excellence [webpage on the Internet]Venous thromboembolic diseases: the management of venous thromboembolic diseases and the role of thrombophilia testing. Clinical guidelines, CG1442012 Available from: http://guidance.nice.org.uk/CG144Accessed September 25, 2015
   Google Scholar
• KearonCAklEAComerotaAJAmerican College of Chest PhysiciansAntithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelinesChest20121412 supple419Se494S22315268
   PubMed Web of Science ®Google Scholar
• EikelboomJWWeitzJINew anticoagulantsCirculation2010121131523153220368532
   PubMed Web of Science ®Google Scholar
• ErikssonBIQuinlanDJEikelboomJWNovel oral factor Xa and thrombin inhibitors in the management of thromboembolismAnnu Rev Med201162415721226611
   PubMed Web of Science ®Google Scholar
• The EINSTEIN InvestigatorsBauersachsRBerkowitzSDOral rivaroxaban for symptomatic venous thromboembolismN Engl J Med2010363262499251021128814
   PubMed Web of Science ®Google Scholar
• The EINSTEIN–PE InvestigatorsBüllerHRPrinsMHOral rivaroxaban for the treatment of symptomatic pulmonary embolismN Engl J Med2012366141287129722449293
   PubMed Web of Science ®Google Scholar
• AgnelliGBullerHRCohenAAMPLIFY InvestigatorsOral apixaban for the treatment of acute venous thromboembolismN Engl J Med2013369979980823808982
   PubMed Web of Science ®Google Scholar
• The Hokusai-VTE InvestigatorsBüllerHRDécoususHEdoxaban versus warfarin for the treatment of symptomatic venous thromboembolismN Engl J Med2013369151406141523991658
   PubMed Web of Science ®Google Scholar
• SchulmanSKearonCKakkarAKRE-COVER Study GroupDabigatran versus warfarin in the treatment of acute venous thromboembolismN Engl J Med2009361242342235219966341
   PubMed Web of Science ®Google Scholar
• SchulmanSKakkarAKGoldhaberSZRE-COVER II Trial InvestigatorsTreatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysisCirculation2014129776477224344086
   PubMed Web of Science ®Google Scholar
• PrinsMHLensingAWABauersachsREINSTEIN InvestigatorsOral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studiesThromb J20131112124053656
   PubMedGoogle Scholar
• SchulmanSKearonCKakkarAKRE-MEDY Trial InvestigatorsRE-SONATE Trial InvestigatorsExtended use of dabigatran, warfarin, or placebo in venous thromboembolismN Engl J Med2013368870971823425163
   PubMed Web of Science ®Google Scholar
• BecattiniCAgnelliGSchenoneAWARFASA InvestigatorsAspirin for preventing the recurrence of venous thromboembolismN Engl J Med2012366211959196722621626
   PubMed Web of Science ®Google Scholar
• BrightonTAEikelboomJWMannKASPIRE InvestigatorsLow-dose aspirin for preventing recurrent venous thromboembolismN Engl J Med2012367211979198723121403
   PubMed Web of Science ®Google Scholar
• MantJHobbsFDRFletcherKBAFTA investigatorsMidland Research Practices Network (MidReC)Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged study, BAFTA): a randomised controlled trialLancet2007370958649350317693178
   PubMed Web of Science ®Google Scholar
• KonstantinidesSVTorbickiAAgnelliG2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolismEur Heart J201435433033306925173341
   PubMed Web of Science ®Google Scholar
• ColemanCIRobertsMSSobierajDMLeeSAlamTKaurREffect of dosing frequency on chronic cardiovascular disease medication adherenceCurr Med Res Opin201228566968022429067
   PubMed Web of Science ®Google Scholar
• BamberLWangMYPrinsMHPatient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic deep-vein thrombosisThromb Haemost2013110473274123846019
   PubMed Web of Science ®Google Scholar
• PrinsMHBamberLCanoSJPatient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of pulmonary embolism; results from the EINSTEIN PE trialThromb Res2015135228128825483215
   PubMed Web of Science ®Google Scholar
• BaglinTKeelingDKitchenSBritish Committee for Standards in HaematologyEffects on routine coagulation screens and assessment of anticoagulant intensity in patients taking oral dabigatran or rivaroxaban: guidance from the British Committee for Standards in HaematologyBr J Haematol2012159442742922970737
   PubMed Web of Science ®Google Scholar
• HeidbuchelHVerhammePAlingsMEuropean Heart Rhythm AssociationEuropean Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillationEuropace201315562565123625942
   PubMed Web of Science ®Google Scholar
• BauersachsRMLensingAWAPrinsMHRivaroxaban versus enoxaparin/vitamin K antagonist therapy in patients with venous thromboembolism and renal impairmentThromb J2014122525750589
   PubMedGoogle Scholar
• CapodannoDAngiolilloDJAntithrombotic therapy in patients with chronic kidney diseaseCirculation2012125212649266122644369
   PubMed Web of Science ®Google Scholar
• DavidsonBLVerheijenSLensingAWABleeding risk of patients with acute venous thromboembolism taking nonsteroidal anti- inflammatory drugs or aspirinJAMA Intern Med2014174694795324733305
   PubMed Web of Science ®Google Scholar
• BounameauxHPerrierADuration of anticoagulation therapy for venous thromboembolismHematology Am Soc Hematol Educ Program2008125225819074092
   PubMedGoogle Scholar
• EikelboomJWGinsbergJSHirshJAnticoagulation for venous thromboembolismBMJ2007334759564517395904
   PubMed Web of Science ®Google Scholar
• PrinsMHLensingAWABrightonTAOral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trialsLancet Haematol201411e37e4627030066
   PubMed Web of Science ®Google Scholar
• BatesSMGreerIAMiddeldorpSAmerican College of Chest PhysiciansVTE, thrombophilia, antithrombotic therapy, and pregnancy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelinesChest20121412 supple691Se736S22315276
   PubMed Web of Science ®Google Scholar
• HeidbuchelHVerhammePAlingsMUpdated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillationEuropace201517101467150726324838
   PubMed Web of Science ®Google Scholar
• DevereauxPJAndersonDRGardnerMJDifferences between perspectives of physicians and patients on anticoagulation in patients with atrial fibrillation: observational studyBr Med J200132373231218122211719412
   PubMed Web of Science ®Google Scholar
• TorbickiAPerrierAKonstantinidesSESC Committee for Practice Guidelines (CPG)Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC)Eur Heart J200829182276231518757870
   PubMed Web of Science ®Google Scholar
• BoutitieFPinedeLSchulmanSInfluence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants’ data from seven trialsBr Med J2011342d303621610040
   PubMed Web of Science ®Google Scholar
• EichingerSHeinzeGJandeckLMKyrlePARisk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism: the Vienna prediction modelCirculation2010121141630163620351233
   PubMed Web of Science ®Google Scholar
• TosettoAIorioAMarcucciMPredicting disease recurrence in patients with previous unprovoked venous thromboembolism: a proposed prediction score (DASH)J Thromb Haemost20121061019102522489957
   PubMed Web of Science ®Google Scholar
• NietoJASolanoRRuiz-RibóMDRiete InvestigatorsFatal bleeding in patients receiving anticoagulant therapy for venous thromboembolism: findings from the RIETE registryJ Thromb Haemost2010861216122220345727
   PubMed Web of Science ®Google Scholar
• NijkeuterMSöhneMTickLWChristopher Study InvestigatorsThe natural course of hemodynamically stable pulmonary embolism: clinical outcome and risk factors in a large prospective cohort studyChest2007131251752317296656
   PubMed Web of Science ®Google Scholar